Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cineverse Corp.CIDM · Entity 7143 | Director | December 12, 2018 | December 19, 2018 |
| XYNOMIC PHARMACEUTICALS HOLDINGS, INC.BCACU · Entity 157082 | COO & Secretary | June 19, 2017 | June 20, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cineverse Corp.
Report date December 12, 2018 · Filed December 19, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 74,712 |
Reported balance
After 2018-12-12 transaction · row 1
1 source rowRow 1 · 2018-12-12 · Grant · Acquired 43,103 · Balance 74,712 F1: Includes 43,103 shares of Class A Common Stock issued on December 12, 2018 as part of the annual retainer for board service by the Reporting Person for the period from October 1, 2018 to September 30, 2019. Such shares vest as follows: 10,776 on each of December 2018, March 31, 2019 and June 30, 2019 and 10,775 on September 30, 2019, so long as the Reporting Person is a director on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 43,103 shares of Class A Common Stock issued on December 12, 2018 as part of the annual retainer for board service by the Reporting Person for the period from October 1, 2018 to September 30, 2019. Such shares vest as follows: 10,776 on each of December 2018, March 31, 2019 and June 30, 2019 and 10,775 on September 30, 2019, so long as the Reporting Person is a director on each such date.
XYNOMIC PHARMACEUTICALS HOLDINGS, INC.
Report date June 19, 2017 · Filed June 20, 2017
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 12, 2018 Filed Dec 19, 2018 22:15 UTC | Cineverse Corp. CIDM · Entity 7143 | GrantClass A Common Stock | 43,103 | $0.00 | $0.00 |
DisclosureSEC source: 0000932440-18-000115 · edgar.xml · nonDerivative · entry 1 Jin Peng · CIK 0001705814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,712 F1 · shares: Includes 43,103 shares of Class A Common Stock issued on December 12, 2018 as part of the annual retainer for board service by the Reporting Person for the period from October 1, 2018 to September 30, 2019. Such shares vest as follows: 10,776 on each of December 2018, March 31, 2019 and June 30, 2019 and 10,775 on September 30, 2019, so long as the Reporting Person is a director on each such date. Read SEC document |
| January 29, 2018 Filed Jan 30, 2018 19:22 UTC | Cineverse Corp. CIDM · Entity 7143 | GrantClass A Common Stock | 31,609 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002233 · doc4.xml · nonDerivative · entry 1 Jin Peng · CIK 0001705814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,609 F1 · shares: Includes 31,609 shares of Class A Common Stock issued on January 29, 2018 as part of the annual retainer for board service by the Reporting Person for the period from November 1, 2017 to September 30, 2018. Such shares vest as follows: 5,746 shares immediately, and 8,621 shares on each of March 31, 2018, June 30, 2018 and September 30, 2018, so long as the Reporting Person is a director on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.